StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Get Rating) in a report issued on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright restated a buy rating and set a $10.00 price target on shares of Pulmatrix in a research report on Tuesday, February 7th. Pulmatrix […]
Haug Partners Successfully Defends Takeda s Vyvanse® Patents At Trial Against Generic Challenge streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
On December 27, 2022, Haug Partners LLP and Gibbons PC obtained a key victory as to all counts for its client, plaintiffs Takeda Pharmaceutical Co. Ltd. and Takeda Pharmaceuticals.